Koninklijke Phil Stock Price, News & Analysis

Philips (NYSE:PHG) and March of Dimes released a comprehensive study revealing a significant support gap for new mothers. The research shows that while 90% of people are willing to help new parents, 62% of mothers struggle to express their support needs, with this figure rising to 76% among Hispanic moms.

Key findings highlight that 2 out of 3 parents need the most support in the first three months postpartum, with 17% of mothers receiving no support outside their spouse. Mental health and self-care emerged as top priorities, with 93% of mothers considering self-care essential, yet 80% get less than an hour of personal time daily. The study also revealed that only 31% of the public are very familiar with postpartum health issues.

Philips (NYSE: PHG) has launched the ECG AI Marketplace, a centralized platform enabling cardiac care teams to access multiple AI-powered diagnostic tools from different vendors. Anumana becomes the first partner, integrating its FDA-cleared ECG-AI™ LEF algorithm for detecting low ejection fraction, an early indicator of heart failure.

The marketplace streamlines workflow integration and vendor management for U.S. hospitals and health systems using Philips' infrastructure. Anumana's algorithm, validated through studies involving over 150,000 patients and supported by nearly 100 peer-reviewed publications, will be available across Philips' ECG portfolio, including IntelliSpace ECG and Philips cardiographs.

Philips (NYSE: PHG) has partnered with Methodist Hospitals to implement advanced image-guided therapy (IGT) solutions across their Northlake and Southlake campuses. The strategic investment includes four new interventional labs featuring Philips Azurion systems, designed for neurovascular, cardiology, and complex interventional radiology procedures.

The implementation includes one Azurion biplane system for stroke intervention, two single plane labs for cardiovascular care, and a multi-purpose lab for complex procedures. The Azurion system has demonstrated a 17% reduction in procedure time, enabling treatment of an additional patient daily. Methodist Hospitals, with over 500 inpatient beds and 400 medical professionals, will utilize Philips' IntraSight with SyncVision technology for enhanced imaging and interventional capabilities.

Philips Foundation released its 2024 Annual Report, marking a decade of impact in healthcare accessibility. The Foundation helped provide quality healthcare access to 46.5 million people worldwide in 2024, up significantly from 28 million in 2023. The organization launched 22 new projects and made 5 new impact investments, expanding its reach in India and South America. Key initiatives included combating neglected diseases like rheumatic heart disease with the World Heart Federation and implementing ultrasound training programs with RAD-AID International. The Foundation continues to progress toward its 2030 goal of reaching 100 million people annually in underserved communities through locally embedded innovation and flexible financing models. Through Philips Foundation Impact Investments, the organization supports healthcare ventures in underserved settings, focusing on financially viable and locally rooted healthcare solutions.

Royal Philips has announced the exchange ratio for its 2024 dividend, offering 1 new common share for every 23.6353 existing shares. The ratio was calculated based on the volume weighted average price of EUR 20.0600 on Euronext Amsterdam over May 30, June 2, and 3, 2025, ensuring the gross dividend in shares approximates EUR 0.85. The company will issue 22,980,748 new common shares, with shareholders having chosen between cash or share dividends. The cash election result was 41.4%, below the 50% maximum threshold, allowing shareholders to receive dividends according to their choice. The dividend distribution, including cash payments and new share delivery, will commence from June 6, 2025. After distribution, Philips' total issued share capital will be EUR 192,584,026, representing 962,920,132 common shares.

Royal Philips (NYSE: PHG) has announced a share repurchase program to acquire up to 6 million shares, valued at approximately EUR 125 million at current prices. The buyback is specifically intended to cover obligations arising from the company's long-term incentive plans. The repurchases will be executed through forward transactions during Q2 and Q3 2025, complying with Market Abuse Regulation and shareholder authorization from May 8, 2025. The company expects to receive the shares in 2027.

Philips (NYSE: PHG) has announced a collaboration with March of Dimes to enhance maternal health education through the Philips Avent Pregnancy+ app. The partnership will integrate March of Dimes content into the app, focusing on critical topics such as NICU preparation, preterm birth, and vaccinations. The Pregnancy+ app, with over 80 million lifetime downloads, offers comprehensive pregnancy guidance including 800+ articles, 3D baby models, and expert-led courses.

The collaboration will emphasize the Low Dose, Big Benefits Campaign, promoting low dose aspirin for preventing pregnancy-related hypertensive disorders. Additionally, both organizations will conduct research using aggregated app data and surveys to gather insights for improving maternal and baby health outcomes.

[ "Partnership with leading nonprofit March of Dimes enhances Philips' maternal health education offering", "Pregnancy+ app has significant market presence with over 80 million lifetime downloads", "Collaboration enables data collection and research opportunities through app analytics and surveys", "Expansion of educational content addressing critical maternal health issues" ]

Philips (NYSE: PHG) has launched the RADIQAL (Radiation Dose and Image Quality Trial) study to evaluate its new ultra-low X-ray dose technology for coronary procedures. The multicenter trial will enroll 824 patients across 6 hospitals in Spain, Czech Republic, Denmark, and the US, with the first patient enrolled at Aarhus University Hospital, Denmark.

The study aims to compare radiation exposure, image quality, and procedural performance between Philips' new ultra-low dose technology and existing ClarityIQ technology, both integrated into the Azurion image-guided therapy system. The new technology features an ultra-low dose protocol that reduces X-ray exposure by 50% compared to the lowest setting currently available on Azurion systems with ClarityIQ. The technology has received CE marking but is not yet FDA-cleared.

Philips (PHG) has launched its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe, following its success in the US. This innovative device features a miniaturized ultrasound probe (3mm diameter) at the tip of a steerable catheter, providing real-time 2D and 3D imaging from inside the heart. The technology enables detailed visualization for structural heart procedures without requiring general anesthesia, offering a more efficient alternative to traditional transesophageal echocardiography (TEE). The catheter integrates with Philips' EPIQ ultrasound systems and Azurion image-guided therapy platform, featuring xPlane and iRotate technologies for precise assessment and device deployment. The launch will be showcased at EuroPCR 2025 in Paris, featuring physician-led symposiums, hands-on training, and VR-based demonstrations.